John W. Davis

John W. Davis, MD

MD Anderson Cancer Center

Houston, Texas

John W. Davis, MD, is a Professor of Urology and Director of the Urosurgical Prostate Program at the University of Texas MD Anderson Cancer Center in Houston. He received his BS in Biology at Davidson College in North Carolina in 1990. He then went on to earn his medical degree at the University of Virginia in 1994 and completed his residency training at Eastern Virginia Graduate School of Medicine in Norfolk. Dr. Davis had fellowship training in prostate cancer research in the Department of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School, and received an American Foundation of Urologic Disease Scholar award for proteomic applications in prostate cancer biomarkers. He completed a Clinical Fellowship in Urologic Oncology at the MD Anderson Cancer Center, and a Fellowship in Laparoscopic Urology at Charité Hospital in Berlin, Germany, under the mentorship of Ingolf Tuerk.

Dr. Davis’ clinical interests include patients with urologic cancers, laparoscopic/robotic surgery, and general urology. His academic interests include quality of life after prostate cancer treatment, outcomes for robotic radical prostatectomy, high-risk prostate cancer trials, active surveillance for prostate cancer, and development of robotic surgical techniques for invasive bladder cancer. He has participated as an investigator in several Southwest Oncology Group and industry-sponsored clinical trials.

Talks by John W. Davis, MD

Point Counterpoint: The Optimal Nadir T Level on ADT Is <20mg/mL

Posted by John W. Davis, MD | Jun 2019

John W. Davis, MD, debates the pros of using <20mg/mL as a threshold for the optimal nadir level of serum testosterone in prostate cancer patients treated with ADT.

Focal Therapy for Localized Prostate Cancer: Is There a “Middle Ground” Between Active Surveillance and Definitive Treatment?

Posted by John W. Davis, MD | May 2019

John W. Davis, MD, discusses the lack of consensus regarding the definitions and benefits of focal therapy for prostate cancer. He defines the patients who would benefit most from focal therapy, as well as overcoming current challenges in this approach.

Robot Assisted Radical Prostatectomy in 2018: My Best Answers to the Most Common Patient Questions

Posted by John W. Davis, MD | Jan 2019

John W. Davis, MD, provides instructions regarding how to build an effective handout for patients prior to robot assisted radical prostatectomy. Specifically, he describes commonly asked patient questions and how to answer in an evidence-based and trustworthy manner.

Prostate Cancer Focal Therapy: Is it the Right Time for your Practice?

Posted by John W. Davis, MD | Dec 2018

John W. Davis, MD, discusses the benefits and limitations of focal therapy for prostate cancer. He describes ways in which focal therapy can be a middle ground between active surveillance and standard therapies, as well as identifying appropriate candidates for this approach.

The Pros and Cons of Genomic Markers for Biopsy Guidance

Posted by John W. Davis, MD | Dec 2018

John W. Davis, MD, discusses the benefits and limitations of utilizing genomic markers for prostate biopsy guidance. While genomic markers may not be reliable risk stratification tools alone, they may play a role in risk-refining certain populations and providing information beyond clinical parameters.